milademetan
Phase 3- Indications
- Dedifferentiated liposarcoma
Company intelligence / Profile preview
Rain Oncology Inc.
Newark, California, United Statesrainoncology.com ↗
- Ownership
- Public · RAIN
- Employees
- ~63
- Development stage
- Phase 3
01
Overview
Lead product milademetan failed in Phase 3 trial for liposarcoma in May 2023, leading to suspension of other trials and workforce reduction of 65%
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Financials
- Market cap
- $7.6M
- Total revenue
- $0
- Enterprise value
- $16.5M
Beyond the preview
Go deeper on Rain Oncology Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rain Oncology Inc..